INS and metabolic dysfunction-associated steatotic liver disease: The FXR represents a relevant clinical target for MASLD treatment [22], since FXR activation has been shown to reduce hepatic and plasma levels of TAGs and liver inflammation [22], while increasing insulin sensitivity [23].